BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

...targets. Nobel Laureate James Allison and Padmanee Sharma joined the company’s scientific advisory board.TARGETSADAMTS5 – ADAM metallopeptidase with thrombospondin...
...activator of transcription 3 (STAT3) Signal transducer and activator of transcription 5 (STAT5) Mu opioid receptor (MOR) (OPRM1) ADAM metallopeptidase with thrombospondin...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

...over seven years and is funded by NIH’s National Institute on Ageing. Targets ADAMTS5 - ADAM metallopeptidase with thrombospondin...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...Italy Samumed LLC, San Diego, Calif. Unity Biotechnology Inc. (NASDAQ:UBX), Brisbane, Calif. Targets ADAMTS5 - ADAM metallopeptidase with thrombospondin...
...SMAD family member 5 Lauren Martz, Associate Editor Galapagos N.V. GeneQuine Biotherapeutics GmbH Rottapharm Biotech s.r.l. Samumed LLC Unity Biotechnology Inc. ADAM metallopeptidase with thrombospondin...
BioCentury | Jul 15, 2019
Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

...this quarter. Gilead was up $1.81 to $68.07. Targets: ENPP2 (ATX) - Autotaxin; ADAMTS5 - ADAM metallopeptidase with thrombospondin...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

...26. Two others could be first-in-class: Maribavir, an oral antiviral, and SHP655, a recombinant human ADAM metallopeptidase with thrombospondin...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

...stroke. University of Plymouth Distillery Therapeutics NMDA receptor NR2D subtype (GRIN2D) Biomarkers Cancer Prostate cancer ADAM metallopeptidase with thrombospondin...
BioCentury | Apr 25, 2018
Translation in Brief

Prostate prognosis

...In addition, 9 of the 97 genes had not been previously associated with any cancer: ADAM metallopeptidase with thrombospondin...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...is in Phase III testing to treat congenital thrombotic thrombocytopenic purpura (cTTP). The recombinant human ADAM metallopeptidase with thrombospondin...
BioCentury | Jan 19, 2018
Clinical News

Galapagos reports Phase Ib data for GLPG1972 in OA

...Servier (Suresnes, France) plan to start a global Phase II program of the inhibitor of ADAM metallopeptidase with thrombospondin...
...Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium Servier, Suresnes, France Product: GLPG1972 Business: Autoimmune Molecular target: ADAM metallopeptidase with thrombospondin...
...percent reduction in ARGS neoepitope Status: Phase Ib data Milestone: Start Phase II (2018) Mary Romeo GLPG1972 Galapagos N.V. Servier ADAM metallopeptidase with thrombospondin...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Musculoskeletal

...ADAMTS1 expression. Ongoing work has included optimizing and testing ADAMTS1 mimetics for undisclosed indications. TARGET/MARKER/PATHWAY: ADAM metallopeptidase with thrombospondin...
...Sept. 22, 2017 doi:10.1038/s41467-017-00522-7 CONTACT: Brian J. Feldman, Stanford University, Stanford, Calif. email: feldman@stanford.edu Claire Quang Stanford University ADAM metallopeptidase with thrombospondin...
Items per page:
1 - 10 of 27